Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Pasadena. CA | Posted on August 18th, 2020

The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL) – August 27-29, 2020

Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Authors: Edward Gane, et al.
Type: Oral Presentation
Date and Time: August 28, 2020 at 13:30 CEST
European Society of Cardiology (ESC) Congress 2020 – August 29 - September 1, 2020

Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency
Authors: Christian Schwabe, et al.
Presenter: Christie M. Ballantyne
Type: Oral Presentation
Date and Time: August 31, 2020 at 10:50 CEST
Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia
Authors: Gerald F. Watts, et al.
Type: Oral Presentation
Date and Time: August 31, 2020 at 11:00 CEST
A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Two opposing approaches could give lithium-sulfur batteries a leg up over lithium-ion July 1st, 2022

Robot nose that can “smell” disease on your breath: Scientists develop diagnostic device for identifying compounds unique to particular diseases July 1st, 2022

Efficiently processing high-quality periodic nanostructures with ultrafast laser July 1st, 2022

Photonic synapses with low power consumption and high sensitivity are expected to integrate sensing-memory-preprocessing capabilities July 1st, 2022

Possible Futures

Technologies boost potential for carbon dioxide conversion to useful products: Researchers explore use metal-organic frameworks based catalysts for hydrogenation of carbon dioxide July 1st, 2022

Sieving carbons: Ideal anodes for high-energy sodium-ion batteries July 1st, 2022

An artificial intelligence probe help see tumor malignancy July 1st, 2022

Photon-controlled diode: an optoelectronic device with a new signal processing behavior July 1st, 2022

Nanomedicine

An artificial intelligence probe help see tumor malignancy July 1st, 2022

Robot nose that can “smell” disease on your breath: Scientists develop diagnostic device for identifying compounds unique to particular diseases July 1st, 2022

From outside to inside: A rapid and precise total assessment method for cells: Researchers at Nara Institute of Science and Technology show that using four frequencies of applied voltage can improve the measurement of cell size and shape during impedance cytometry, enabling to en June 24th, 2022

New technology helps reveal inner workings of human genome June 24th, 2022

Announcements

Two opposing approaches could give lithium-sulfur batteries a leg up over lithium-ion July 1st, 2022

Robot nose that can “smell” disease on your breath: Scientists develop diagnostic device for identifying compounds unique to particular diseases July 1st, 2022

Efficiently processing high-quality periodic nanostructures with ultrafast laser July 1st, 2022

Photonic synapses with low power consumption and high sensitivity are expected to integrate sensing-memory-preprocessing capabilities July 1st, 2022

Events/Classes

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

June Conference in Grenoble, France, to Explore Pathways to 6G Applications, Including ‘Internet of Senses’, Sustainability, Extended Reality & Digital Twin of Physical World: Organized by CEA-Leti, the Joint EuCNC and 6G Summit Sees Telecom Sector as an ‘Enabler for a Sustainabl June 1st, 2022

How a physicist aims to reduce the noise in quantum computing: NAU assistant professor Ryan Behunin received an NSF CAREER grant to study how to reduce the noise produced in the process of quantum computing, which will make it better and more practical April 1st, 2022

Could quantum technology be New Mexico’s next economic boon? Quantum New Mexico Coalition aims to establish state as national hub April 1st, 2022

Nanobiotechnology

Robot nose that can “smell” disease on your breath: Scientists develop diagnostic device for identifying compounds unique to particular diseases July 1st, 2022

From outside to inside: A rapid and precise total assessment method for cells: Researchers at Nara Institute of Science and Technology show that using four frequencies of applied voltage can improve the measurement of cell size and shape during impedance cytometry, enabling to en June 24th, 2022

New technology helps reveal inner workings of human genome June 24th, 2022

Disinfectant mechanism of nano-sized electrostatic atomized water particles on SARS-CoV-2: Nano-sized electrostatic atomized water particles destroy SARS-CoV-2 envelope, protein, and RNA, thereby impairing the virus’s ability to bind to host cells June 17th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project